Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Amrita Krishnan, MD, Antje Hoering, PhD, Parameswaran Hari, MD MRCP, Rachael Sexton, PhD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142913

Published: 2020

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Madhav V Dhodapkar, MD, Rachael Sexton, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2018-99-119634

Published: 2018

Journal Articles

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Sikander Ailawadhi, MD, Susanna Joan Jacobus, MSc, Rachael Sexton, MS, A. Keith Stewart, MD, Angela Dispenzieri, MD, Mohamad A. Hussein, Jeffrey Zonder, MD, John Crowley, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, PhD, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 1192.

https://doi.org/10.1182/blood.V128.22.1192.1192

Published: 2016

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

Madhav V. Dhodapkar, Rachael Sexton, Rituparna Das, Kavita M. Dhodapkar, Lin Zhang, Ranjini Sundaram, Sonal Soni, John J. Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2015) 126 (22): 2475–2478.

https://doi.org/10.1182/blood-2015-03-632919

Published: 2015

Includes: Supplemental data

Journal Articles

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Saad Z. Usmani, MD, Rachael Sexton, Sikander Ailawadhi, MD, Jatin J. Shah, Natalie S Callander, MD, Todd Zimmerman, MD, Jason Valent, MD, Michael Rosenzweig, MD, Brea C. Lipe, MD, Jeffrey Zonder, MD, Sandi Fredette, Brian G. M. Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Paul G. Richardson, Robert Z. Orlowski, PhD MD

Blood (2014) 124 (21): 4762.

https://doi.org/10.1182/blood.V124.21.4762.4762

Published: 2014

Journal Articles

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2014) 123 (1): 78–85.

https://doi.org/10.1182/blood-2013-07-515239

Published: 2014

Includes: Supplemental data

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, PhD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, John Crowley, PhD, Nathan M Petty, Stephen Harding, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 3976.

https://doi.org/10.1182/blood.V120.21.3976.3976

Published: 2012

Journal Articles

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Donald Johann, MD, MS, Pingping Qu, PhD, Rachael Sexton, Antje Hoering, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Frits van Rhee, MD, PhD, Saad Z Usmani, MD FACP, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 3953.

https://doi.org/10.1182/blood.V120.21.3953.3953

Published: 2012

Journal Articles

Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.

Sarah Waheed, MD, Christoph Heuck, MD, Pingping Qu, PhD, Frits van Rhee, MD, PhD, Saad Z Usmani, MD FACP, Qing Zhang, PhD, Rachael Sexton, John Crowley, PhD, Joshua Epstein, DSc, Madhav V. Dhodapkar, MD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 2933.

https://doi.org/10.1182/blood.V120.21.2933.2933

Published: 2012

Journal Articles

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Saad Usmani, MD, FACP, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 2947.

https://doi.org/10.1182/blood.V118.21.2947.2947

Published: 2011

Journal Articles

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Saad Usmani, MD, FACP, Alan Mitchell, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3082.

https://doi.org/10.1182/blood.V118.21.3082.3082

Published: 2011

Journal Articles

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Christoph Heuck, MD, Rachael Sexton, Madhav Dhodapkar, MD, MBBS, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3955.

https://doi.org/10.1182/blood.V118.21.3955.3955

Published: 2011

Journal Articles

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Saad Usmani, MD, FACP, Rachael Sexton, Antje Hoering, PhD, Christoph Heuck, MD, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan M Petty, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 823.

https://doi.org/10.1182/blood.V118.21.823.823

Published: 2011

NARROW

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups

Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only